Entrada Therapeutics, Inc. (TRDA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.41-6.77%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Entrada Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	6.95M
EPS	—	-0.93
Annual ending 2026-12-31
Revenue	—	10.65M
EPS	—	-3.883
Annual ending 2027-12-31
Revenue	—	20.01M
EPS	—	-3.37

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advancement of RNA therapy clinical trials and partnerships	A supporting condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is Sustained clinical trial milestones and new partnerships.	Improving	Failure to advance clinical trials or loss of partnerships	Qualitative: Positive topline data (Oct 2026) vs. sustained milestones target Oct 14, 2026: Positive topline data from Phase 1/2 ELEVATE-45-201 study for ENTR-601-45. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS loss narrows from -$3.79 in 2026 to less negative in 2027	A primary condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves to > -$3.26.	Improving	EPS loss worsens beyond -$3.79 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to reverse decline and approach $29.8M in 2027	A primary condition in Entrada Therapeutics, Inc.'s published investment case. The stated target is >= $29.8 million.	Broken	revenue falls below $15 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.37

$-3.59 → $-3.37 · observed estimates

FY2027 revenue$0.02B

$0.03B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.59	$26,082,875	6 / 5
2026-07-25	$-3.26	$29,809,000	6 / 7
2026-07-26	$-3.59	$26,082,875	6 / 5
2026-07-27	$-3.59	$26,082,875	6 / 5
2026-07-28	$-3.26	$29,809,000	6 / 7
2026-07-29	$-3.59	$26,082,875	6 / 5
2026-07-30	$-3.26	$29,809,000	6 / 7
2026-07-31	$-3.26	$29,809,000	6 / 7
2026-08-01	$-3.59	$26,082,875	6 / 5
2026-08-02	$-3.26	$29,809,000	6 / 7
2026-08-03	$-3.59	$26,082,875	6 / 5
2026-08-04	$-3.26	$29,809,000	6 / 7
2026-08-05	$-3.26	$29,809,000	6 / 7
2026-08-06	$-3.26	$29,809,000	6 / 7
2026-08-08	$-3.50	$25,939,875	6 / 5
2026-08-09	$-3.27	$40,790,000	7 / 5
2026-08-10	$-3.50	$25,939,875	6 / 5
2026-08-12	$-3.50	$25,939,875	6 / 5
2026-08-13	$-3.50	$25,939,875	6 / 5
2026-08-14	$-3.50	$25,939,875	6 / 5
2026-08-15	$-3.50	$25,939,875	6 / 5
2026-08-16	$-3.50	$25,939,875	6 / 5
2026-08-17	$-3.50	$25,939,875	6 / 5
2026-08-18	$-3.50	$25,939,875	6 / 5
2026-08-19	$-3.50	$25,939,875	6 / 5
2026-08-20	$-3.37	$20,002,375	6 / 6
2026-08-21	$-3.37	$20,002,375	6 / 6
2026-08-22	$-3.37	$20,002,375	6 / 6
2026-08-23	$-3.37	$20,002,375	6 / 6
2026-08-24	$-3.37	$20,002,375	6 / 6
2026-08-25	$-3.37	$20,002,375	6 / 6
2026-08-26	$-3.37	$20,002,375	6 / 6
2026-08-27	$-3.37	$20,002,375	6 / 6
2026-08-28	$-3.37	$20,002,375	6 / 6
2026-08-29	$-3.37	$20,002,375	6 / 6
2026-08-30	$-3.37	$20,002,375	6 / 6
2026-08-31	$-3.37	$20,002,375	6 / 6
2026-09-01	$-3.37	$20,002,375	6 / 6
2026-09-02	$-3.37	$20,002,375	6 / 6
2026-09-03	$-3.37	$20,002,375	6 / 6
2026-09-04	$-3.37	$20,002,375	6 / 6
2026-09-05	$-3.37	$20,002,375	6 / 5
2026-09-06	$-3.37	$20,002,375	6 / 5
2026-09-07	$-3.37	$20,002,375	6 / 5
2026-09-08	$-3.37	$20,002,375	6 / 5
2026-09-09	$-3.37	$20,002,375	6 / 5
2026-09-10	$-3.37	$20,002,375	6 / 5
2026-09-11	$-3.37	$20,002,375	6 / 5
2026-09-12	$-3.37	$20,002,375	6 / 5
2026-09-13	$-3.37	$20,002,375	6 / 5
2026-09-14	$-3.37	$20,002,375	6 / 5
2026-09-15	$-3.37	$20,002,375	6 / 5
2026-09-16	$-3.37	$20,002,375	6 / 5
2026-09-17	$-3.37	$20,002,375	6 / 5
2026-09-18	$-3.37	$20,002,375	6 / 5
2026-09-19	$-3.37	$20,002,375	6 / 5
2026-09-20	$-3.37	$20,002,375	6 / 5
2026-09-21	$-3.37	$20,002,375	6 / 5
2026-09-22	$-3.37	$20,002,375	6 / 5
2026-09-23	$-3.37	$20,002,375	6 / 5
2026-09-24	$-3.37	$20,002,375	6 / 5
2026-09-25	$-3.37	$20,002,375	6 / 5
2026-09-26	$-3.37	$20,002,375	6 / 5
2026-09-27	$-3.37	$20,002,375	6 / 5
2026-09-28	$-3.37	$20,002,375	6 / 5
2026-09-29	$-3.37	$20,002,375	6 / 5
2026-09-30	$-3.37	$20,002,375	6 / 5
2026-10-01	$-3.37	$20,002,375	6 / 5
2026-10-02	$-3.37	$20,002,375	6 / 5
2026-10-03	$-3.37	$20,002,375	6 / 5
2026-10-04	$-3.37	$20,002,375	6 / 5
2026-10-05	$-3.37	$20,002,375	6 / 5
2026-10-06	$-3.37	$20,002,375	6 / 5
2026-10-07	$-3.37	$20,002,375	6 / 5
2026-10-08	$-3.37	$20,002,375	6 / 5
2026-10-09	$-3.37	$20,002,375	6 / 5
2026-10-10	$-3.37	$20,002,375	6 / 5
2026-10-11	$-3.37	$20,002,375	6 / 5
2026-10-12	$-3.37	$20,002,375	6 / 5
2026-10-13	$-3.37	$20,002,375	6 / 5
2026-10-14	$-3.37	$20,002,375	6 / 5
2026-10-15	$-3.37	$20,006,250	6 / 5
2026-10-16	$-3.37	$20,006,250	6 / 5
2026-10-17	$-3.37	$20,006,250	6 / 5
2026-10-18	$-3.37	$20,006,250	6 / 5
2026-10-19	$-3.37	$20,006,250	6 / 5
2026-10-20	$-3.37	$20,006,250	6 / 5
2026-10-21	$-3.37	$20,006,250	6 / 5
2026-10-22	$-3.37	$20,006,250	6 / 5
2026-10-23	$-3.37	$20,006,250	6 / 5
2026-10-24	$-3.37	$20,006,250	6 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows from -$3.79 in 2026 to less negative in 2027Direct metric needs a verified mapping
Revenue growth to reverse decline and approach $29.8M in 2027Published status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-72.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Entrada Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, not a business with established earnings: it is loss-making and its value depends on future drug development. The long-term thesis is in a watch state, with recent progress on clinical data but elevated risk and performance below its industry cohort.

What's priced into Entrada Therapeutics, Inc.

The evidence indicates TRDA is expensive versus peers, and valuation is mainly driven by the possibility that its programs create future value. The expectations gap is notable, but model confidence is low, so the evidence does not establish precisely what the market assumes.

What the fundamentals likely do

Near term, management is delivering on its data-readout priority, including positive topline ELEVATE-45-201 Cohort 1 data reported in October 2026; further DMD data are expected by year-end. Cash resources declined to $223.0 million by 2026-Q2, with management projecting runway into Q3 2027, so continued cash burn remains a key constraint. Recent earnings beats are positive, but a guidance cut, weaker financial performance, or the October litigation filing could weigh on execution and confidence.

What Entrada Therapeutics, Inc. hinges on

The multi-year thesis hinges on whether upcoming clinical data support continued progress in the DMD programs and whether management can advance them within its stated cash runway. Near term, a guidance cut or further weakening in jobs data could add pressure; stronger results and guidance from Healthcare sector leaders could support sector momentum, though they would not resolve TRDA’s clinical and funding risks.